Arrowhead Pharmaceuticals (ARWR) said Thursday it has presented preclinical data supporting two RNA-interference-based investigational therapeutics it is developing, with the potential to reduce body weight and fat mass and preserve lean muscle mass compared with currently approved obesity therapies.
Data from its ARO-INHBE candidate preclinical results showed a 19% suppression in body weight gain relative to vehicle controls, while data from its ARO-ALK7 candidate preclinical results showed a 39% suppression, the company said.
Arrowhead is currently conducting phase 1/2 clinical studies of the two candidates. The company expects initial data from its ARO-INHBE study year-end 2025, and anticipates dosing in the ARO-ALK7 study to begin in the second quarter with initial data from the single-ascending dose portion of the study possible also by year-end 2025.
The company presented the data at the RNA Leaders Europe Congress 2025 held March 4-6 in Basel, Switzerland.
Price: 16.89, Change: -0.46, Percent Change: -2.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.